Newsletter
| Promoter: | Penny Stock General | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| IBIO | No compensation | UNKNOWN |
| Max Profit: 11.69 % | Gain at close: 2.41 % | |
| *We think that this promoter is a part of a group of promoters. | ||
 |
|---|
|
iBio Inc (IBIO)
Morning,
I hope our alert in IBIO today has made up for yesterday.
IBIO opened at $0.40 and climbed slowly to hit a high this morning of $0.4690 for a very achievable 17% gain.
Of course we are always looking for more gains, but IBIO gave us a nice steady winner.
Keep watching this throughout the day though, it's very liquid, and there may be dip buying opportunities and further gains to be had.
All the best.
FastMoneyAlerts.com
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Traders,
Last night I promised you a big board momentum trade, and here it is.
Get iBio Inc (IBIO) on your screen now - don't delay!!! Look at the chart below and see the strong sideways consolidation and recent support at $0.35, just below the current price.
The chart shows possible resistance at $0.45, but after that the next stop could be in the mid $0.50's
We see strong potential gains in IBIO with a solid risk v reward trading profile.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production.
Further information is available at their website: www.ibioinc.com
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf
Make sure you get IBIO on your screen now, this could move fast today.
The Team Get our alerts faster, follow us on Twitter @fastmoneyalerts
|
|
------------------------------------------------------------------------------------------------------------ DISCLAIMER --------------------------------------------------------------------------------------------------------------- Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Fastmoneyalerts.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in Fastmoneyalerts.com statements and opinions and such statements and opinions cannot be considered independent. Fastmoneyalerts.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, Fastmoneyalerts.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. Fastmoneyalerts.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile.
Fastmoneyalerts.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated fastmoneyalerts.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If Fastmoneyalerts.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.
Fastmoneyalerts.com has not been compensated for this profile of IBIO. |